Use of propranolol for treatment of hemangiomas in PHACE syndrome

J Perinatol. 2011 Nov;31(11):739-41. doi: 10.1038/jp.2011.28.

Abstract

We report the case of a 29-week preterm infant with PHACE (posterior fossa malformations, hemangionas, arterial anomalies, cardiac anomalies, eye anomalies) syndrome. PHACE syndrome is a neurocutaneous disorder with large facial segmental hemangionas associated with anomalies of the brain, eye, heart and aorta. The hemangiomas in our patient were problematic, distorting the airway and interfering with respirations to the point of requiring mechanical ventilation. Consultation with several different centers with medical expertize in treatment of congenital hemangiomas revealed different views on the best management strategy. In this infant, the hemangiomas progressed with failure to involute despite currently recommended therapy including corticosteroids and vincristine. Therefore, the infant was treated with propranolol and had significant regression of the hemangiomas. The use of propranolol for the treatment of infantile hemangiomas is reviewed.

Publication types

  • Case Reports

MeSH terms

  • Abnormalities, Multiple*
  • Adrenergic beta-Antagonists / therapeutic use*
  • Facial Neoplasms / congenital*
  • Facial Neoplasms / drug therapy*
  • Female
  • Hemangioma / congenital*
  • Hemangioma / drug therapy*
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Propranolol / therapeutic use*
  • Skin Neoplasms / congenital*
  • Skin Neoplasms / drug therapy*
  • Syndrome

Substances

  • Adrenergic beta-Antagonists
  • Propranolol